lorlatinib-resistant ALK mutants

Stable Identifier
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Lorlatinib is a third generation tyrosine kinase inhibitor with effectiveness against ALK and ROS rearranged cancers. This pathway describes ALK mutants that are resistant to inhibition by lorlatinib (Yoda et al, 2018; Takahashi et al, 2020; reviewed in Della Corte et al, 2018; Lin et al, 2017; Facchinietti et al, 2016).

Literature References
PubMed ID Title Journal Year
27413712 Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Bria, E, Graziano, P, Rossi, G, Novello, S, Di Maio, M, Tiseo, M, Facchinetti, F

Transl Lung Cancer Res 2016
31943796 Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer

Uchibori, K, Yanagitani, N, Tsukahara, M, Okubo, K, Nishio, M, Seto, Y, Okada, K, Takahashi, K, Oh-Hara, T, Uematsu, S, Fujita, N, Katayama, R

Thorac Cancer 2020
29455642 Role and targeting of anaplastic lymphoma kinase in cancer

Troiani, T, Viscardi, G, Morgillo, F, Fasano, M, Martinelli, E, Ciardiello, F, Della Corte, CM, Di Liello, R

Mol. Cancer 2018
29650534 Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Mino-Kenudson, M, Friboulet, L, Benes, CH, Engelman, JA, Yoda, S, Gainor, JF, Dardaei, L, Iafrate, AJ, Heist, RS, Shaw, AT, Dagogo-Jack, I, Langenbucher, A, Burke, BJ, Hata, AN, Ferris, LA, Timonina, D, Johnson, TW, Hubbeling, H, Timofeevski, S, Lawrence, MS, Kattermann, KE, Lin, JJ, Prutisto-Chang, K, Riley, AK, Lennerz, JK

Cancer Discov 2018
28122866 Targeting ALK: Precision Medicine Takes on Drug Resistance

Shaw, AT, Riely, GJ, Lin, JJ

Cancer Discov 2017
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!